Inventor · disambiguated record
Ho-Wah Hui
Also filed as: HUI HO-WAH
24 granted patents·7 pending applications·231 citations·filing 1989–2023
95Inventor score
Top patents by PatentIndex Score
31 records- 0196US9695146B2Solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereofCELGENE CORP·Filed 2014·Granted Jul 4, 2017·17 cites·43 claims
- 0293US11129821B2Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2019·Granted Sep 28, 2021·5 cites·26 claims
- 0393US10052315B2Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2017·Granted Aug 21, 2018·11 cites·50 claims
- 0491US10376503B2Solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereofCELGENE CORP·Filed 2018·Granted Aug 13, 2019·2 cites·38 claims
- 0590US10449187B2Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2018·Granted Oct 22, 2019·6 cites·13 claims
- 0688US9974780B2Solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereofCELGENE CORP·Filed 2017·Granted May 22, 2018·2 cites·38 claims
- 0788US9403829B2Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their useSIGNAL PHARM LLC·Filed 2012·Granted Aug 2, 2016·13 cites·29 claims
- 0887US6010718AExtended release formulations of erythromycin derivativesABBOTT LAB·Filed 1997·Granted Jan 4, 2000·115 cites·16 claims
- 0982US9968627B2Solid forms comprising 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one and a coformer, compositions and methods of use thereofCELGENE CORP·Filed 2014·Granted May 15, 2018·2 cites·21 claims
- 1079US9808450B2Solid forms comprising 3-(4-amino-1-OXO-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereofCELGENE CORP·Filed 2014·Granted Nov 7, 2017·1 cites·38 claims
- 1179US8524148B2Method of integrating therapeutic agent into a bioerodible medical deviceSHRIVASTAVA SANJAY·Filed 2006·Granted Sep 3, 2013·5 cites·2 claims
- 1277US11883389B2Formulations of 2-(4-chlorophenyl)-N-((2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2021·Granted Jan 30, 2024·0 cites·23 claims
- 1373US11406629B2Solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereofCELGENE CORP·Filed 2020·Granted Aug 9, 2022·0 cites·27 claims
- 1471US10835522B2Solid forms comprising 4-amino-2-(2,6- dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereofCELGENE CORP·Filed 2019·Granted Nov 17, 2020·0 cites·38 claims
- 1568US9532977B2Controlled release oral dosage forms of poorly soluble drugs and uses thereofCELGENE CORP·Filed 2015·Granted Jan 3, 2017·1 cites·1 claims
- 1668US2015051157A1Romidepsin formulations and uses thereofCELGENE CORP·Filed 2014·Application pending·0 cites
- 1767US9795650B2Romidepsin formulations and uses thereofCELGENE CORP·Filed 2016·Granted Oct 24, 2017·0 cites·12 claims
- 1867US9782451B2Romidepsin formulations and uses thereofCELGENE CORP·Filed 2016·Granted Oct 10, 2017·0 cites·12 claims
- 1967US9023886B2Nanosuspension of a poorly soluble drug via microfluidization processCHEN MING J·Filed 2010·Granted May 5, 2015·1 cites·10 claims
- 2065US9463215B2Romidepsin formulations and uses thereofCELGENE CORP·Filed 2015·Granted Oct 11, 2016·0 cites·6 claims
- 2164US9884042B2Formulations of cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amideBOERSEN NATHAN·Filed 2012·Granted Feb 6, 2018·2 cites·12 claims
- 2264US2015182584A1Romidepsin formulations and uses thereofCELGENE CORP·Filed 2014·Application pending·0 cites
- 2360US9468664B2Romidepsin formulations and uses thereofCELGENE CORP·Filed 2015·Granted Oct 18, 2016·0 cites·6 claims
- 2460US2025255781A1Processes for preparation of 3-d printed pharmaceutical productsBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 2560US2013184225A1Romidepsin formulations and uses thereofHUANG LIANFENG·Filed 2013·Application pending·0 cites
- 2659US2016367625A1Romidepsin formulations and uses thereofCELGENE CORP·Filed 2016·Application pending·0 cites
- 2758US5082656ATopical antibacterial compositions containing penetration enchancersABBOTT LAB·Filed 1989·Granted Jan 21, 1992·48 cites·11 claims
- 2857US2018000808A1Solid forms comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereofCELGENE CORP·Filed 2017·Application pending·0 cites
- 2946US9616019B2Nanosuspension of a poorly soluble drug via microfluidization processCELGENE CORP·Filed 2015·Granted Apr 11, 2017·0 cites·10 claims
- 3045US9757355B2Oral dosage forms of cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amideCHEN MING J·Filed 2012·Granted Sep 12, 2017·0 cites·5 claims
- 3140US2014018404A1Controlled release oral dosage forms of poorly soluble drugs and uses thereofCHEN MING J·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →